Daré Bioscience, Inc.DARENASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank87
3Y CAGR-23.1%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
-23.1%/yr
vs +162.4%/yr prior
Acceleration
-185.5pp
Decelerating
Percentile
P87
Within normal range
vs 3Y Ago
0.5x
Contraction
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 91.84% |
| Q2 2025 | 0.97% |
| Q1 2025 | -204.67% |
| Q4 2024 | 188.23% |
| Q3 2024 | -145.91% |
| Q2 2024 | 289.41% |
| Q1 2024 | 16.70% |
| Q4 2023 | -2.57% |
| Q3 2023 | -21.07% |
| Q2 2023 | 59.14% |
| Q1 2023 | -173.33% |
| Q4 2022 | -168.56% |
| Q3 2022 | 201.80% |
| Q2 2022 | 31.55% |
| Q1 2022 | -24.48% |
| Q4 2021 | -851.02% |
| Q3 2021 | 111.20% |
| Q2 2021 | -40.76% |
| Q1 2021 | 8.88% |
| Q4 2020 | -71.63% |
| Q3 2020 | -31.07% |
| Q2 2020 | 38.05% |
| Q1 2020 | -73.22% |
| Q4 2019 | -19.77% |
| Q3 2019 | -5.36% |
| Q2 2019 | 8.77% |
| Q1 2019 | -22.07% |
| Q4 2018 | 1.46% |
| Q3 2018 | -2.30% |
| Q2 2018 | -26.89% |
| Q1 2018 | -120.47% |
| Q4 2017 | -106.95% |
| Q3 2017 | 355.48% |
| Q2 2017 | 45.84% |
| Q1 2017 | -433.33% |
| Q4 2016 | 73.81% |
| Q3 2016 | 36.30% |
| Q2 2016 | 15.23% |
| Q1 2016 | -61.51% |
| Q4 2015 | -3.05% |